

Product datasheet

anti-AAV VP1 mouse monoclonal, A1, lyophilized, purified

Short overview

Cat. No.	61056
Quantity	50 µg
Concentration	50 μ g/ml after reconstitution with 1 ml sterile PBS

Product description

Host	Mouse
Antibody Type	Monoclonal
lsotype	IgG2a
Clone	A1
Immunogen	AAV2 capsids
Formulation	Lyophilized; reconstitute in 1 ml sterile PBS
Conjugate	Unconjugated
Purification	Affinity chromatography
Storage before	2-8°C until indicated expiry date
reconstitution	
Storage after	Up to 3 months at 2-8°C; long term storage in aliquots at -20°C; avoid freeze/thaw cycles
reconstitution	
Intended use	Research use only
Application	ELISA, ICC/IF, IP, WB
Reactivity	AAV1, AAV2, AAV3, AAV5, AAV6, AAV7, AAV8, AAV9, AAVDJ
Storage before reconstitution Storage after reconstitution Intended use Application	2-8°C until indicated expiry date Up to 3 months at 2-8°C; long term storage in aliquots at -20°C; avoid freeze/thaw cycles Research use only ELISA, ICC/IF, IP, WB

Applications

ELISA		
Immunocytochemistry (ICC)		
Immunoprecipitation (IP)		
Western Blot (WB)		


Assay dependent Assay dependent Assay dependent 1:500 (0.1 µg/ml)

Background

A1 reacts with VP1 of adeno-associated virus 1-9 and DJ (AAV1-9, DJ). In immunoprecipitation, an occasional reaction with a non-AAV-derived protein is found. Epitope mapping experiments (Wobus et al. 2000) identified aa123 to aa131 of VP1 capsid protein as the specific binding region.

Wobus, C. E. et al. Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virol. 74, 928193 (2000).

Product images




Western blot analysis of AAV2 capsids with anti-AAV VP1 antibody. Western blot analysis was performed on either 3.0E+09 or 1.0E+09 AAV2 capsids. The PVDF membrane was blocked with 5% dry milk in PBST for 1 h at RT. The primary antibody anti-AAV VP1, mouse monoclonal, A1 was diluted in blocking buffer (antibody concentration 0.1 μ g/ml) and incubated for 1 h at RT. The secondary antibody goat anti-mouse IgG polyclonal, HRP conjugate was also diluted in blocking buffer (antibody concentration 0.2 μ g/ml) and incubated for 1 h at RT. The bands were visualized by chemiluminescent detection using PierceTM ECL Western Blotting Substrate.

A1 epitopes in AAV serotypes

NUT DUIT POT OT UT TO A VIEW DOUT OGDO
AV1 AKKRVLEPLGLVEEGAKTAPGKKRPVEQSPQ
AV2 AKKRVLEPLGLVEEPVKTAPGKKRPVEHSPV
AV3B AKKRILEPLGLVEEAAKTAPGKKRPVDQSPQ
AV4 AKKRVLEPLGLVEQAGETAPGKKRPLIESPQ
AV5 AK <mark>KRVLEP</mark> F <mark>GL</mark> VEEGAKTAPTGKRIDDHFPK
AV6 AK <mark>KRVLEP</mark> F <mark>GL</mark> VEEGAKTAPGKKRPVEQSPQ
AV7 AKKRVLEPLGLVEEGAKTAPAKKRPVEPSPQ
AV8 AKKRVLEPLGLVEEGAKTAPGKKRPVEPSPQ
AV9 AK <mark>KRLLEPLGL</mark> VEEAAKTAPGKKRPVEQSPQ
AVrh10 AK <mark>KRVLEPLGL</mark> VEEAAKTAPGKKRPVEPSPQ
AVhu.37 AKKRVLEPLGLVEEAAKTAPGKKRPVEPSPQ
AVrh74 AKKRVLEPLGLVESPVKTAPGKKRPVEPSPQ

Alignment of A1 epitopes in different AAV serotypes.



Western blot analysis of denatured AAV1-AAV9, AAVrh10, AAVDJ capsids (5E+09 capsids, denatured at 95°C for 10 min in sample buffer) and recombinant AAV2 VP1/VP2/VP3-Mix (50 ng, Cat. No. 72001). The PVDF membrane was blocked with 5% dry milk in PBST (PBS + 0.1% Tween 20) for 1 h at RT. The primary antibody anti-AAV VP1, mouse monoclonal, A1 was diluted in blocking buffer (antibody concentration 100 ng/ml) and incubated for 1 h at RT. The secondary antibody goat anti-mouse IgG HRP was also diluted in blocking buffer (antibody concentration 200 ng/ml) and incubated for 1 h at RT. The bands were visualized by chemiluminescent detection using Pierce ECL Western Blotting Substrate.

References

Publication	Species	Application
Mietzsch, M. et al. OneBac: Platform for Scalable and	AAV1,AAV2,AAV3,AAV4,AAV	WB
High-Titer Production of Adeno-Associated Virus Serotype	5,AAV6,AAV7,AAV8,AAV9,AA	
1–12 Vectors for Gene Therapy. Hum. Gene Ther. 25,	Vrh10,AAV11,AAV12	
<u>212–222 (2014)</u> .		
Grimm, D., Kay, M. A. & Kleinschmidt, J. A. Helper virus-free,	AAV2	WB
optically controllable, and two-plasmid-based production of		
adeno-associated virus vectors of serotypes 1 to 6. Mol. Ther.		
<u>7, 839–850 (2003).</u>		
Wobus, C. E. et al. Monoclonal antibodies against the	AAV2	epitope mapping
adeno-associated virus type 2 (AAV-2) capsid: epitope		
mapping and identification of capsid domains involved in		
AAV-2-cell interaction and neutralization of AAV-2 infection. J.		
<u>Virol. 74, 9281–93 (20</u>		
Wistuba, A. et al. Subcellular Compartmentalization of	AAV2	WB,ICC-IF
Adeno-Associated Virus Type 2 Assembly. J. Virol. 71,		
<u>1341–1352 (1997).</u>		
·		